Case study
Metastatic bladder cancer: a complete response to immunotherapy
- Patient
- Man, 58
- Diagnosis
- Bladder cancer, stage IIIB at diagnosis, later spread to the lymph nodes
- Outcome
- Complete response on PET/CT and long-term disease control
Background
In 2021 the patient was diagnosed with a bladder tumor that had grown into the surrounding tissue and lymph nodes.
He had several cycles of chemotherapy and surgery to remove the bladder.
But in December 2021 a follow-up PET/CT showed the disease had progressed and spread to the lymph nodes.
Treatment
In January 2022 he started immunotherapy with avelumab.
Treatment lasted about five months, and he received 11 cycles.
Despite a good response, the drug had to be stopped because of a serious kidney complication. After that he was monitored without treatment for 1 year and 10 months.
Results
As early as March 2022 a follow-up PET/CT showed clear improvement:
- The affected lymph node had halved in size.
- Its metabolic activity had dropped to background levels.
PET/CT showed a complete metabolic response: the scan no longer detected increased tumor activity in the target lesion.
PET/CT before and after immunotherapy
3 December 2021 — progression
30 March 2022 — complete metabolic response
Coronal view, lymph node marked with an arrow
Further follow-up
In February 2024 scans showed the disease had progressed again. He was started on a different immunotherapy, pembrolizumab.
By April 2024 a follow-up PET/CT showed improvement: the affected lymph nodes were smaller and less active, and there were no new lesions.
Even after the second progression, the new treatment worked. At the last available scan he was continuing immunotherapy under the care of an oncologist.
Follow-up PET/CT, March 2022
The arrow marks the lymph node, now smaller, with activity down to background.
A case from my practice. Personal details have been removed from the images. The latest results shown are from April 2024. Treatment results vary, and other patients may respond differently.
